Recent Quotes
My Watchlist
Indicators
Star 60
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

160.75 +0.35 (+0.22%)
Official Closing Price Updated: 7:00 PM EDT, May 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,509,606
Open 160.71
Bid (Size) 160.00 (2)
Ask (Size) 161.22 (4)
Prev. Close 160.40
Today's Range 160.35 - 161.44
52wk Range 130.96 - 182.89
Shares Outstanding N/A
Dividend Yield 3.68%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Earn $1000 Every Month From These 3 Stocks
All 3 companies pay growing dividends. 
Via The Motley Fool
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.
These pharmaceutical companies are top-notch dividend growth stocks for the future. 
Via The Motley Fool

Performance

YTD
+0.58%
+0.58%
1 Month
-4.90%
-4.90%
3 Month
-7.66%
-7.66%
6 Month
+15.99%
+15.99%
1 Year
+18.29%
+18.29%

More News

Read More
(ABBV) - Analyzing AbbVie's Short Interest
Via Benzinga
3 Rock-Solid Dividend Stocks That Are Ideal for Retirees
Via The Motley Fool
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
Via InvestorPlace
AbbVie Tracking for New Highs in 2024
Via MarketBeat
Topics Earnings
Exposures Financial
3 Reasons to Buy AbbVie Stock on the Dip
Via The Motley Fool
$1000 Invested In This Stock 10 Years Ago Would Be Worth $3,100 Today
Via Benzinga
Peeling Back The Layers: Exploring AbbVie Through Analyst Insights
Via Benzinga
3 Biotech Stocks to Double Your Money in the Next 24 Months
Via InvestorPlace
MarketBeat Week in Review – 4/29 - 5/3
Via MarketBeat
Topics Economy Stocks
Exposures Interest Rates US Equities
7 Safe Haven Stocks That Can Withstand the Market’s Worst Meltdowns
Via InvestorPlace
Analyst Sentiment, Revenue Growth Will Lead AbbVie Stock Higher
Via MarketBeat
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
Via Benzinga
Topics Stocks
Exposures US Equities
Inflation-Proof Fortunes: 7 Dividend Aristocrats to Keep Your Wealth Growing
Via InvestorPlace
Topics Economy
Exposures Interest Rates
AbbVie Outlook: Why Humira Biosimilars Won't Undo A Projected $73 Billion In Sales
Via Investor's Business Daily
Better Dividend Stock: AbbVie or Johnson & Johnson?
Via The Motley Fool
3 Dividend Stocks to Buy and Hold for the Next Decade
Via The Motley Fool
Why AbbVie Stock Stumbled Today Despite the Earnings Beat
Via The Motley Fool
AbbVie (ABBV) Q1 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Arthritis Patients - Cigna's Evernorth To Offer Humira Biosimilar At No Out-of-Pocket Cost
Via Benzinga
Tech Stocks Rebound As Magnificent 7 Roar On Strong Earnings, Energy Giants Tumble: What's Driving Markets Friday?
Via Benzinga
Topics Economy
Exposures Interest Rates
ABBV Stock Earnings: AbbVie Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Ex-Humira Growth Platform Drives AbbVie's Q1 Performance, Drugmaker Lifts Annual Profit Outlook
Via Benzinga
AbbVie Beats First-Quarter Views As Skyrizi Looks To Take Humira's Title
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.